Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug combination improves or stabilizes disease for relapsed multiple myeloma patients

10.12.2008
Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

Interim results of an ongoing clinical trial evaluating pomalidomide, a new immunomodulatory agent, combined with dexamethasone (pom/dex), were presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco. Pomalidomide, also referred to as CC-4047, is the latest in the class of immunomodulatory agents that also includes thalidomide and lenalidomide.

Multiple myeloma (http://www.mayoclinic.org/multiple-myeloma/) is a cancer of the plasma cells, a type of white blood cells in the bone marrow, that affects approximately 3 in 100,000 people each year. There is no cure. While the condition can be managed, often with good results, the disease can lead to erosion of the bones, causing bone pain and fractures.

Immunomodulatory drugs work by interfering with cancer cell growth and by stimulating the immune system to attack the cancer cells. The Food and Drug Administration (FDA) has approved the use of thalidomide and lenalidomide to be given with dexamethasone for previously treated cases of multiple myeloma.

The study opened in November 2007 and has accrued 60 patients. To date, 58 percent of patients have responded to therapy with at least a 50 percent drop in the detectable tumor burden as measured by blood protein levels, a marker for myeloma. This included one patient who achieved a complete remission -- no signs of the cancer -- and 14 patients (23 percent) who achieved at least a 90 percent drop in blood proteins. Eleven other patients (18 percent) remained stable.

"These are high remission rates, and they happened quickly," says Martha Lacy, M.D. (http://www.mayoclinic.org/bio/11115891.html), Mayo Clinic hematologist and lead researcher on the study. Also encouraging, says Dr. Lacy, is that treatment did not cause significant side effects in most patients. Side effects included anemia and declines in blood counts, most often mild in both.

In the study, patients took pomalidomide (2 milligrams [mg]) orally daily for a 28-day cycle. Dexamethasone (40 mg) was taken orally on days 1, 8, 15 and 22 of each cycle. Patients also took 325 mg of aspirin daily to prevent blood clots, a concern associated with immunomodulatory agents. Blood clots can occur with use of any IMiD, but the risk increases as the dose of dexamethasone increases.

The dosage of dexamethasone in the current trial is one-third of the dose that was used in the registration trial that led to FDA approval for lenalidomide in previously treated myeloma patients. "We're getting good results with less toxicity compared to what we've seen in the past," says Dr. Lacy. "And, so far, no patients have had blood clots."

Another key finding was that pom/dex was helpful for 29 percent of patients who previously did not respond to treatment with lenalidomide.

"We are excited about the potential of this drug combination to significantly help patients with myeloma," says Dr. Lacy. "Based on these encouraging results, we are expanding the study to include other patient populations that may benefit from this therapy."

Amy Tieder | EurekAlert!
Further information:
http://www.mayo.edu
http://www.mayoclinic.org/bio/11115891.html
http://www.mayoclinic.org/multiple-myeloma

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Individualized fiber components for the world market

23.06.2017 | Physics and Astronomy

How brains surrender to sleep

23.06.2017 | Life Sciences

Can we see monkeys from space? Emerging technologies to map biodiversity

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>